Otsuka’s $886M-plus drug just flopped in its first crucial PhIII trial for frontline AML
Five years ago Otsuka swept in and scooped up California-based Astex for $886 million, determined to get its hands on their promising leukemia drug SGI …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
